⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACTU News
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
globenewswire.com
ACTU
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
globenewswire.com
ACTU
Form 8-K
sec.gov
ACTU
Form 8-K
sec.gov
ACTU
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
globenewswire.com
ACTU
Form 8-K
sec.gov
ACTU
GSK
MRK
SNX
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
globenewswire.com
ACTU
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
globenewswire.com
ACTU
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
accessnewswire.com
ACTU
RVMD
ERAS
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
globenewswire.com
ACTU